Point72 Asset Management L.P. bought a new stake in DBV Technologies S.A. (NASDAQ:DBVT) during the first quarter, according to its most recent filing with the SEC. The fund bought 31,800 shares of the company’s stock, valued at approximately $1,120,000. Point72 Asset Management L.P. owned approximately 0.07% of DBV Technologies as of its most recent SEC filing.
A number of other hedge funds have also recently added to or reduced their stakes in DBVT. Parametric Portfolio Associates LLC raised its position in shares of DBV Technologies by 9.2% in the first quarter. Parametric Portfolio Associates LLC now owns 33,270 shares of the company’s stock worth $1,172,000 after buying an additional 2,794 shares during the period. Jennison Associates LLC raised its position in shares of DBV Technologies by 0.7% in the first quarter. Jennison Associates LLC now owns 537,726 shares of the company’s stock worth $18,939,000 after buying an additional 3,577 shares during the period. Emory University raised its position in shares of DBV Technologies by 7.9% in the first quarter. Emory University now owns 62,884 shares of the company’s stock worth $2,215,000 after buying an additional 4,628 shares during the period. Victory Capital Management Inc. bought a new position in shares of DBV Technologies during the first quarter worth $303,000. Finally, Sphera Funds Management LTD. raised its position in shares of DBV Technologies by 14.1% in the first quarter. Sphera Funds Management LTD. now owns 90,167 shares of the company’s stock worth $3,176,000 after buying an additional 11,109 shares during the period. 48.23% of the stock is owned by hedge funds and other institutional investors.
DBV Technologies S.A. (NASDAQ:DBVT) opened at 38.02 on Wednesday. The company’s 50 day moving average is $34.16 and its 200 day moving average is $34.70. DBV Technologies S.A. has a 12-month low of $31.87 and a 12-month high of $38.41. The firm’s market cap is $1.75 billion.
COPYRIGHT VIOLATION WARNING: “Point72 Asset Management L.P. Takes Position in DBV Technologies S.A. (DBVT)” was originally reported by BBNS and is the sole property of of BBNS. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://baseballnewssource.com/markets/point72-asset-management-l-p-takes-position-in-dbv-technologies-s-a-dbvt/1180521.html.
A number of brokerages have weighed in on DBVT. BidaskClub upgraded shares of DBV Technologies from a “strong sell” rating to a “sell” rating in a report on Wednesday, June 21st. ValuEngine lowered shares of DBV Technologies from a “hold” rating to a “sell” rating in a report on Friday, June 30th. Zacks Investment Research upgraded shares of DBV Technologies from a “sell” rating to a “hold” rating in a report on Thursday, April 6th. Morgan Stanley reiterated an “overweight” rating on shares of DBV Technologies in a report on Monday. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $47.00 price target on shares of DBV Technologies in a report on Thursday, June 1st. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $47.00.
About DBV Technologies
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
Receive News & Ratings for DBV Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies S.A. and related companies with our FREE daily email newsletter.